Floatz logo

azd0120

Idiopathic Inflammatory Myopathies

AstraZenecaCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Idiopathic Inflammatory Myopathies cohort.

Asset / SponsorPhaseRating
Filgotinib
UMC Utrecht
Phase 2CCC
Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy
Beijing Boren Hospital
Phase 1CC
hbi0101 cart
Polina Stepensky
Phase 1CC
her2bbζ/cd19t+ t cells
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early Phase 1C
ct103a cells
Tongji Hospital
Early Phase 1C
Cyclophosphamide
Tongji Hospital
Early Phase 1C
Fludarabine
Tongji Hospital
Early Phase 1C

Same molecule, other indications

azd0120 is also rated in:

plasma cell myelomaDormant
B
Indicative ·
58 / 100
View asset →
systemic sclerosisDormant
CC
Indicative ·
43 / 100
View asset →
rheumatoid arthritisDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →